Study of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer (MK-7962-012)
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Sponsor: Merck Sharp & Dohme LLC
Terminated
administrative reasons (slow patient enrollment)
A PHASE2 clinical study on Chemotherapy Induced Anemia, this trial is terminated or withdrawn. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 13 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE2
-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Terminated PHASE2
▶ Show 8 earlier versions
-
Jan 2023 — Oct 2023 [monthly]
Terminated PHASE2
-
Apr 2022 — Jan 2023 [monthly]
Terminated PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Terminated PHASE2
-
Nov 2019 — Jan 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Nov 2019 [monthly]
Terminated PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Feb 2017 — Dec 2017 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Jun 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .